Skip to main content
Clinical Trials/JPRN-UMIN000002177
JPRN-UMIN000002177
Completed
Phase 4

Prospective randomized controlled trial Comparing Peg-IFN alpha-2a monotherapy versus Peg-IFN alpha-2a +ribavirin combination therapy after curative ablation for HCV-positive Hepatocellular Carcinoma - Comparing Peg-IFN alpha-2a(+RBV) for HCV-positive hepatocellular carcinoma patients after curative ablation.

Yokohama City University Medical Center Gastroenterological Center0 sites95 target enrollmentJuly 10, 2009

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Chronic hepatitis C Hepatocellular carcinoma
Sponsor
Yokohama City University Medical Center Gastroenterological Center
Enrollment
95
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 10, 2009
End Date
May 31, 2016
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Yokohama City University Medical Center Gastroenterological Center

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Patient with 1\.pregnant or lactating women and women who may be pregnant 2\. a man who can not avoid conception during administration of ribavirin and until 6 month after the end ribavirin treatment 3\. allergic to ribavirin or nucleoside analogues 4\.hemoglobinopathy(thalassemia, sickle cell disease) 5\.an uncontrollable heart trouble (myocardial infarction, heart failure, or arrhythmia) 6\.an poorly controlled diabetes mellitus and hypertension 7\. severe renal disease, Ccr \<50ml/min 8\. severe depression or psychosomatic disorders 9 .liver disease such as autoimmune hepatitis 10\.clinical laboratory date does not meet selection criterion 11\. drug allergy against interferon

Outcomes

Primary Outcomes

Not specified

Similar Trials